Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders

Academic Article
Publication Date:
2025
Short description:
Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders / Masciocchi, S., Businaro, P., Greco, G., Scaranzin, S., Malvaso, A., Morandi, C., Zardini, E., Risi, M., Vegezzi, E., Diamanti, L., Bini, P., Siquilini, S., Giannoccaro, M.P., Morelli, L., Liguori, R., Patti, F., De Giuli, V., Portaccio, E., Zanetta, C., Bergamoni, S., et al.. - In: NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION. - ISSN 2332-7812. - 12:2(2025). [10.1212/NXI.0000000000200359]
abstract:
Background and ObjectivesAntibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum. METHODS We devised a new live cell-based assay (CBA) for PLP1-IgG and used it to test 2 cohorts (retrospective exploratory, n = 284; prospective validation, n = 824) of patients with ADDs and controls (n = 177). Patients were classified as MS, neuromyelitis optica spectrum disorders (NMOSDs), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and other ADDs. PLP1-IgG-positive samples were tested for IgG subclasses, DM20-IgG, and on rat brain tissue-based ...
Iris type:
1.1 Articolo in rivista
List of contributors:
Masciocchi, S.; Businaro, P.; Greco, G.; Scaranzin, S.; Malvaso, A.; Morandi, C.; Zardini, E.; Risi, M.; Vegezzi, E.; Diamanti, L.; Bini, P.; Siquilini, S.; Giannoccaro, M. P.; Morelli, L.; Liguori, R.; Patti, F.; De Giuli, V.; Portaccio, E.; Zanetta, C.; Bergamoni, S.; Simone, A. M.; Lanzillo, R.; Bruno, G.; Gallo, A.; Bisecco, A.; Di Filippo, M.; Pauri, F.; Toriello, A.; Barone, P.; Tazza, F.; Bucello, S.; Banfi, P.; Fabris, M.; Volonghi, I.; Raciti, L.; Vigliani, M. C.; Bocci, T.; Paoletti, M.; Colombo, E.; Filippi, M.; Pichiecchio, A.; Marchioni, E.; Franciotta, D.; Gastaldi, M.
Authors of the University:
FILIPPI MASSIMO
Handle:
https://iris.unisr.it/handle/20.500.11768/178036
Full Text:
https://iris.unisr.it//retrieve/handle/20.500.11768/178036/272580/Neurol%20Neuroimmunol%20Neuroinflamm%2012_e200359.pdf
Published in:
NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION
Journal
  • Overview

Overview

URL

https://www.neurology.org/doi/10.1212/NXI.0000000000200359
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.2.0